Pharmaceuticals discovered with AI
EFFICIENT DRUG DISCOVERY & DEVELOPMENT
twoXAR Pharmaceuticals is a drug discovery and development company focused on first-in-class small molecules. The company currently has a development portfolio of over 18 diseases. twoXAR saves years in drug development while generating a 30x hit rate at in vivo efficacy milestones over traditional methods.
WEBINAR SERIES
Part 1: SVP R&D, Mark Eller discusses the role of AI in the drug discovery ecosystem
Part 2: VP Discovery, Aaron Daugherty shares how we collaborate with our partners
Part 3: SVP Nonclinical R&D & Chemistry, Anjali Pandey provides insight on what's next for twoXAR
LATEST NEWS
LATEST EVENTS
(Digital)
January 11-15, 2021
twoXAR Pharmaceuticals CEO Andrew Radin presents on the company's capabilities in discovering first-in-class small molecules.
Using Artificial Intelligence in Drug Discovery
CM Life Sciences (Digital)
December 3, 2020
twoXAR Pharmaceuticals CEO Andrew A. Radin joins a webinar hosted by CM Life Sciences to discuss harnessing AI in drug discovery.
EPPIC Global Presents: Role of AI/ML in transforming and accelerating the drug discovery process
EPPIC Global (Digital)
October 17, 2020
twoXAR Pharmaceuticals SVP Nonclinical R&D & Chemistry Anjali Pandey moderates a panel including twoXAR CEO Andrew Radin, along with representatives from Recursion Pharma, ATOM Consortium, and NuMedii.
© 2020 twoXAR, Incorporated | All Rights Reserved